Parametric Portfolio Associates LLC boosted its position in NxStage Medical, Inc. (NASDAQ:NXTM) by 33.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 61,104 shares of the medical device company’s stock after purchasing an additional 15,388 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.09% of NxStage Medical worth $1,532,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in NXTM. Quantitative Systematic Strategies LLC acquired a new position in NxStage Medical in the 2nd quarter valued at about $203,000. Amalgamated Bank raised its stake in NxStage Medical by 7.1% in the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after purchasing an additional 553 shares during the last quarter. Suntrust Banks Inc. raised its stake in NxStage Medical by 2.3% in the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after purchasing an additional 209 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in NxStage Medical by 217.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock valued at $243,000 after purchasing an additional 6,624 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in NxStage Medical in the 2nd quarter valued at about $269,000. 92.31% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total transaction of $102,235.00. Following the completion of the sale, the senior vice president now owns 16,270 shares in the company, valued at approximately $475,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $29.22, for a total value of $125,646.00. Following the sale, the senior vice president now owns 28,721 shares of the company’s stock, valued at approximately $839,227.62. The disclosure for this sale can be found here. Insiders have sold a total of 17,600 shares of company stock valued at $496,902 in the last quarter. Company insiders own 4.70% of the company’s stock.

NXTM has been the subject of a number of research analyst reports. Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research note on Tuesday, October 17th. BidaskClub downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Zacks Investment Research downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $28.00 to $30.00 in a research note on Tuesday, August 22nd. Finally, Craig Hallum downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $30.25.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/parametric-portfolio-associates-llc-has-1-53-million-position-in-nxstage-medical-inc-nxtm/1699484.html.

NxStage Medical, Inc. (NASDAQ NXTM) opened at $25.79 on Monday. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.